Gaining Ground: UroGen Pharma Ltd (URGN) Closes Lower at 18.59, Down -7.10

In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.

The price of UroGen Pharma Ltd (NASDAQ: URGN) closed at $18.59 in the last session, down -7.10% from day before closing price of $20.01. In other words, the price has decreased by -$7.10 from its previous closing price. On the day, 1.82 million shares were traded. URGN stock price reached its highest trading level at $19.7263 during the session, while it also had its lowest trading level at $17.08.

Ratios:

We take a closer look at URGN’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.47 and its Current Ratio is at 5.65.

On April 16, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $23.Scotiabank initiated its Sector Outperform rating on April 16, 2025, with a $23 target price.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jul 28 ’25 when Smith Jason Drew sold 7,522 shares for $19.14 per share. The transaction valued at 143,971 led to the insider holds 41,492 shares of the business.

Schoenberg Mark sold 5,149 shares of URGN for $98,552 on Jul 28 ’25. The Chief Medical Officer now owns 158,229 shares after completing the transaction at $19.14 per share. On Jul 28 ’25, another insider, Schoenberg Mark, who serves as the Officer of the company, bought 5,149 shares for $18.95 each.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, URGN now has a Market Capitalization of 924488128 and an Enterprise Value of 853083072. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.35. Its current Enterprise Value per Revenue stands at 9.286 whereas that against EBITDA is -8.004.

Stock Price History:

The Beta on a monthly basis for URGN is 1.12, which has changed by 0.26807642 over the last 52 weeks, in comparison to a change of 0.18634176 over the same period for the S&P500. Over the past 52 weeks, URGN has reached a high of $21.01, while it has fallen to a 52-week low of $3.42. The 50-Day Moving Average of the stock is 38.95%, while the 200-Day Moving Average is calculated to be 62.74%.

Shares Statistics:

According to the various share statistics, URGN traded on average about 3.12M shares per day over the past 3-months and 1235950 shares per day over the past 10 days. A total of 46.10M shares are outstanding, with a floating share count of 39.68M. Insiders hold about 14.11% of the company’s shares, while institutions hold 103.01% stake in the company. Shares short for URGN as of 1752537600 were 7293235 with a Short Ratio of 2.34, compared to 1749772800 on 6125129. Therefore, it implies a Short% of Shares Outstanding of 7293235 and a Short% of Float of 16.03.

Earnings Estimates

The performance of UroGen Pharma Ltd (URGN) in the stock market is under the watchful eye of 7.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.43, with high estimates of -$0.1 and low estimates of -$0.69.

Analysts are recommending an EPS of between -$3.37 and -$3.37 for the fiscal current year, implying an average EPS of -$3.37. EPS for the following year is -$1.04, with 7.0 analysts recommending between $2.04 and -$3.09.

Revenue Estimates

According to 8 analysts, the current quarter’s revenue is expected to be $33.57M. It ranges from a high estimate of $42.1M to a low estimate of $28.2M. As of the current estimate, UroGen Pharma Ltd’s year-ago sales were $25.2MFor the next quarter, 8 analysts are estimating revenue of $44.31M. There is a high estimate of $52.41M for the next quarter, whereas the lowest estimate is $35.23M.

A total of 8 analysts have provided revenue estimates for URGN’s current fiscal year. The highest revenue estimate was $136M, while the lowest revenue estimate was $111.5M, resulting in an average revenue estimate of $122.26M. In the same quarter a year ago, actual revenue was $90.4MBased on 8 analysts’ estimates, the company’s revenue will be $263.59M in the next fiscal year. The high estimate is $391.48M and the low estimate is $224.3M.

Leave a Reply

Your email address will not be published. Required fields are marked *

DWinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.